FDA clears a WAT Medical 510(k) for its HeadaTerm for treating migraine headaches.
Federal Register notice: FDA announces the renewal of its Oncologic Drugs Advisory Committee for an additional two years beyond the charter expiration...
Severing FDAs historical independence from drug economics, commissioner Scott Gottlieb suggests that new innovative payment/reimbursement mechanisms s...
Federal Register notice: FDA seeks comments on a proposed information collection entitled Clinical Use of Bulk Drug Substances Nominated for Use in Co...
Pharmaceutical Research and Manufacturers of America says it supports FDAs efforts to identify alternative or streamlined mechanisms for complying wit...
FDA hosts a 10/15-16 public workshop to convene a discussion on methodological approaches that may be used to develop and identify what is most import...
House Republicans derail a Trump-supported legislative measure that would have required drug companies to include prices in their direct-to-consumer a...
Federal Register notice: FDA announces an 11/28 public workshop entitled Pathogen Reduction Technologies for Blood Safety.